Trial reportBMC cancer2019
Association of breast and gut microbiota dysbiosis and the risk of breast cancer: a case-control clinical study.
Trial report in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03885648 (Association of Breast and Gut Microbiota Dysbiosis and the Risk of Breast Cancer), which is not on this map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Association of Breast and Gut Microbiota Dysbiosis and the Risk of Breast Cancer
Who cites it
77 citing papers in PubMed.
- The gut-tumor connection: the role of microbiota in cancer progression and treatment strategies.Journal of advanced research · 2026Review
- Causal relationship between GM, immune cells and esophageal adenocarcinoma: a mediation analysis based on MR.Journal of cardiothoracic surgery · 2026Article
- Bidirectional Communication of Estrogen in Gut-Brain Axis: Evidence from Preclinical and Clinical Studies.Current drug targets · 2026Review
- Dual Biological Effects and Mechanisms of Gut Microbiota in Breast Cancer: A Review.Current pharmaceutical biotechnology · 2026Review
- The role of gut microbiota and its metabolites in preventing oncogenesis.Frontiers in cell and developmental biology · 2026Review
- Gut microbiome dysbiosis and antimicrobial resistance in the Middle East: a converging public health crisis in conflict and fragile settings.Archives of microbiology · 2025Review
- Guardians in the Gut: Mechanistic Insights into a Hidden Ally Against Triple-Negative Breast Cancer.Cancers · 2025Review
- Longitudinal changes in gut microbiota composition during endocrine therapy in hormone receptor-positive breast cancer patients.NPJ breast cancer · 2025Article
- Microbial Signatures in Breast Cancer: Exploring New Potentials Across Body Niches.International journal of molecular sciences · 2025Review
- Investigating the Alleviating Effects of Dihydromyricetin on Subclinical Mastitis in Dairy Cows: Insights from Gut Microbiota and Metabolomic Analysis.Microorganisms · 2025Article
- The East Asian gut microbiome and its role in oncology: a narrative review.Singapore medical journal · 2025Review
- Review
- Comparison of Three DNA Isolation Methods and Two Sequencing Techniques for the Study of the Human Microbiota.Life (Basel, Switzerland) · 2025Article
- Integrated microbiome and metabolome analysis reveals altered gut microbial communities and metabolite profiles in dairy cows with subclinical mastitis.BMC microbiology · 2025Article
- Dysbiosis and extraintestinal cancers.Journal of experimental & clinical cancer research : CR · 2025Review
- Development of a risk prediction nomogram model of pyrotinib-induced severe diarrhea.BMC cancer · 2025Article
- Preliminary investigation of gut microbiota and associated metabolic pathways in the pathogenesis of primary central nervous system lymphoma.Frontiers in oncology · 2025Article
- Host-microbe-cancer interactions on-a-chip.Frontiers in bioengineering and biotechnology · 2025Review
- Gut microbiota-derived formate exacerbates pulmonary metastasis in cancer.Theranostics · 2025Article
- Obesity and cancer: unravelling the microbiome's hidden role.Frontiers in nutrition · 2025Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundBreast cancer ranks first in women, and is the second cause of death in this gender. In addition to genetics, the environment contributes to the development of the disease, although the factors involved are not well known. Among the latter is the influence of microorganisms and, therefore, attention is recently being paid to the mammary microbiota. We hypothesize that the risk of breast cancer could be associated with the composition and functionality of the mammary/gut microbiota, and that exposure to environmental contaminants (endocrine disruptors, EDCs) might contribute to alter these microbiota.
methodsWe describe a case-control clinical study that will be performed in women between 25 and 70 years of age. Cases will be women diagnosed and surgically intervened of breast cancer (stages I and II). Women with antecedents of cancer or advanced tumor stage (metastasis), or who have received antibiotic treatment within a period of 3 months prior to recruitment, or any neoadjuvant therapy, will be excluded. Controls will be women surgically intervened of breast augmentation or reduction. Women with oncological, gynecological or endocrine history, and those who have received antibiotic treatment within a period of 3 months prior to recruitment will also be excluded. Blood, urine, breast tissue and stool samples will be collected. Data regarding anthropometric, sociodemographic, reproductive history, tumor features and dietary habits will be gathered. Metabolomic studies will be carried out in stool and breast tissue samples. Metagenomic studies will also be performed in stool and breast tissue samples to ascertain the viral, fungal, bacterial and archaea populations of the microbiota. Quantitation of estrogens, estrogen metabolites and EDCs in samples of serum, urine and breast tissue will also be performed. DISCUSSION: This is the first time that the contribution of bacteria, archaea, viruses and fungi together with their alteration by environmental contaminants to the risk of breast cancer will be evaluated in the same study. Results obtained could contribute to elucidate risk factors, improve the prognosis, as well as to propose novel intervention studies in this disease.
trial registrationClinicalTrials.gov NCT03885648 , 03/25/2019. Retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.